Nintedanib (Ofev®)

Status
To Patients
Condition
Systemic Sclerosis ILD
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

Nintedanib (Ofev®): Nintedanib is an anti-fibrotic drug that is approved to treat Systemic Sclerosis ILD in the United States. In clinical trials, nintedanib has been shown to slow the progression of lung function decline in this patient population.

More Information

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >